logo

Provention Bio, Inc. (PRVB)



Trade PRVB now with
  Date
  Headline
8/4/2022 7:56:43 AM Provention Bio Q2 Net Loss $29.7 Mln, Or $0.46/shr Vs Net Loss Of $29.1 Mln Or $0.46/shr Prior Year
6/3/2022 7:36:32 AM Provention Bio Grants Stock Options To Eight New Employees To Purchase 166,000 Shares
3/28/2022 7:39:26 AM Provention Bio Reports Positive Final Results From First-In-Human Study Of Coxsackievirus B Vaccine Candidate PRV-101
2/24/2022 7:20:36 AM Provention Bio Q4 Net Loss $25.8 Mln Or $0.41/shr Vs Net Loss Of $32.6 Mln Or $0.58/shr Prior Year
2/22/2022 7:32:32 AM Provention Bio Resubmits BLA For Teplizumab For Delay Of Clinical Type 1 Diabetes In At-risk Individuals
1/7/2022 7:32:33 AM Provention Bio Announces The Grant Of Inducement Awards
12/20/2021 7:34:00 AM Provention Bio Announces Leadership Team Expansion (Press Release)
12/2/2021 7:33:21 AM Provention Bio Announces Grant Of Inducement Awards To Purchase An Aggregate Of 550K Shares
11/4/2021 7:20:59 AM Resolute Forest Products Q3 EPS $0.99 Vs. $0.66 Last Year
11/4/2021 7:16:30 AM Provention Bio Says Appoints Thierry Chauche As CFO
10/26/2021 7:34:42 AM Provention Bio Reports Positive Interim Results From First-In-Human Study Of Coxsackievirus B Vaccine Candidate PRV-101
7/6/2021 7:05:38 AM FDA Issues CRL For Provention Bio's Teplizumab For Delay Of Clinical Type 1 Diabetes In At-risk Individuals